Renal-cell carcinoma--molecular pathways and therapies

N Engl J Med. 2007 Jan 11;356(2):185-7. doi: 10.1056/NEJMe068263.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Gene Silencing
  • Humans
  • Hypoxia-Inducible Factor 1 / genetics
  • Hypoxia-Inducible Factor 1 / metabolism
  • Indoles / therapeutic use*
  • Kidney Neoplasms / drug therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Platelet-Derived Growth Factor / antagonists & inhibitors
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Kinases / metabolism
  • Pyridines / therapeutic use*
  • Pyrroles / therapeutic use*
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Receptors, Vascular Endothelial Growth Factor / metabolism
  • Sorafenib
  • Sunitinib
  • TOR Serine-Threonine Kinases
  • Von Hippel-Lindau Tumor Suppressor Protein / genetics

Substances

  • Angiogenesis Inhibitors
  • Benzenesulfonates
  • Hypoxia-Inducible Factor 1
  • Indoles
  • Phenylurea Compounds
  • Platelet-Derived Growth Factor
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Von Hippel-Lindau Tumor Suppressor Protein
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Receptors, Vascular Endothelial Growth Factor
  • Sunitinib